急性髓系白血病患者CD34、CD123、CD38的表达及其临床意义

Expressions of CD34, CD123 and CD38 in acute myelogenous leukemia and their clinical significances

目的 探讨急性髓系白血病（AML）患者CD34、CD123、CD38的表达及其临床意义.方法 收集2014年2月至2015年7月中南大学湘雅医院164例AML患者,用流式细胞术检测患者细胞免疫分型.根据CD34、CD38、CD123的表达情况,将患者分成阳性组与阴性组,对两组的临床资料及骨髓象进行比较分析.结果 164例AML患者中,CD34阳性102例,阳性率62.2％;CD123阳性126例,阳性率76.8％;CD38阳性144例,阳性率88.3％.各项阳性组与阴性组患者年龄、性别比较差异均无统计学意义（P〉0.05）;两组患者骨髓中幼稚细胞比例、白细胞计数及血红蛋白水平比较差异均有统计学意义（均P〈0.05）.CD34、CD38、CD123表达率与微小残留病发生率、疾病完全缓解率有相关性（均P〈0.05）.结论 CD34、CD123、CD38是AML检测的有效标志物,其表达可作为细胞成熟度的判断标志,有利于AML患者病情及预后的判定.

Objective To investigate the expressions of CD34, CD123 and CD38 in acute myelogenous leukemia （AML） and their clinical significances. Methods A total of 164 patients with AML in Xiangya Hospital of Central South University from February 2014 to July 2015 were enrolled. Cellular immunophenotyping was performed by flow cytometry. According to the expressions of CD34, CD38 and CD123, 164 patients were divided into positive group and negative group, and the clinical data and immature cells ratio of two groups were compared. Results In 164 patients with AML, 102 cases （62.2 %） were CD34 positive, 126 cases （76.8%） were CD123 positive, and 144 cases （88.3%） were CD38 positive. There were no significant differences in age and sex between the positive and negative groups （P〉 0.05）. But there were significant differences in the proportion of immature cells, white blood cell count and hemoglobin between the two groups （all P〈 0.05）. The expression rates of CD34, CD38 and CD123 were correlated with minimal residual disease and complete remission rate （all P〈 0.05）. Conclusions CD34, CD123 and CD38 are effective markers for AML detection. The expressions of CD34, CD123 and CD38 can be used as the judgment marker of cell maturity, which is conducive to the determination of the condition and prognosis of AML patients.